PR Newswire BiotechOriginal article
Chemo-Resistant Pancreatic Tumor Liquefies and Drains Several Months after Receiving Proprietary Intratumoral EpCAM/CD3 Vaccine
Data ReadoutpositiveEpCAM/CD3 VaccineGemcitabinePositive
AI Analysis
Summary
A peer-reviewed case report documents a proprietary intratumoral EpCAM/CD3 vaccine achieving 90% tumor volume reduction with extensive necrosis in a chemo-resistant pancreatic cancer patient after gemcitabine failure, without surgery or full-dose chemotherapy.
Outcome Details
Peer-reviewed case report documents 90% volume reduction with extensive necrosis in chemo-resistant pancreatic tumor after intratumoral EpCAM/CD3 vaccine, achieved without surgery or full-dose chemotherapy
Importance:5/10
Sentiment:
0.70
oncologypancreatic cancerimmunotherapyvaccinecase reportintratumoral
Read the original article
Published by PR Newswire Biotech on September 7, 2026 4:55 PM